Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non–small cell lung cancer

Lung cancer is the leading cause of cancer‐related deaths worldwide. Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKI) often have good clinical activity against non–small cell lung cancer (NSCLC) with activating EGFR mutations. Osimertinib, which is a third‐generation EGFR‐TKI,...

Descripción completa

Detalles Bibliográficos
Autores principales: Akazawa, Yu, Saito, Yuki, Yoshikawa, Toshiaki, Saito, Keigo, Nosaka, Kazuto, Shimomura, Manami, Mizuno, Shoichi, Nakamoto, Yasunari, Nakatsura, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419036/
https://www.ncbi.nlm.nih.gov/pubmed/32391625
http://dx.doi.org/10.1111/cas.14451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419036/
https://www.ncbi.nlm.nih.gov/pubmed/32391625
http://dx.doi.org/10.1111/cas.14451

Ejemplares similares